Raju Prasad's most recent trade in CRISPR Therapeutics AG was a trade of 19,500 Restricted Stock Units done . Disclosure was reported to the exchange on May 29, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2026 | 19,500 | 19,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2026 | 38,499 | 38,499 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2026 | 27,500 | 27,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2026 | 6,250 | 19,273 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2026 | 6,250 | 12,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 46.78 per share. | 20 Mar 2026 | 3,708 | 15,565 (0%) | 0% | 46.8 | 173,460 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 10,000 | 16,767 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 6,875 | 23,642 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 6,875 | 20,625 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 48.26 per share. | 14 Mar 2026 | 5,848 | 17,794 (0%) | 0% | 48.3 | 282,224 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 48.26 per share. | 14 Mar 2026 | 4,021 | 13,773 (0%) | 0% | 48.3 | 194,053 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Mar 2026 | 750 | 13,023 (0%) | 0% | 0 | Common Shares | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.15 per share. | 22 Jan 2026 | 34,972 | 41,739 (0%) | 0% | 45.2 | 1,578,986 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2026 | 34,972 | 41,667 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.19 per share. | 22 Jan 2026 | 34,972 | 6,767 (0%) | 0% | 60.2 | 2,104,965 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.15 per share. | 06 Jan 2026 | 23,361 | 30,128 (0%) | 0% | 45.1 | 1,054,749 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 23,361 | 76,639 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.18 per share. | 06 Jan 2026 | 18,933 | 17,534 (0%) | 0% | 60.2 | 1,139,386 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.31 per share. | 06 Jan 2026 | 6,339 | 36,467 (0%) | 0% | 44.3 | 280,881 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2026 | 6,339 | 7,493 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.21 per share. | 06 Jan 2026 | 5,763 | 6,767 (0%) | 0% | 60.2 | 347,010 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 06 Jan 2026 | 5,004 | 12,530 (0%) | 0% | 60 | 300,240 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 56.33 per share. | 22 Dec 2025 | 5,472 | 7,767 (0%) | 0% | 56.3 | 308,262 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 55.10 per share. | 22 Dec 2025 | 3,528 | 13,239 (0%) | 0% | 55.1 | 194,401 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 56.89 per share. | 22 Dec 2025 | 1,000 | 6,767 (0%) | 0% | 56.9 | 56,886 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2025 | 16,500 | 16,500 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 6,250 | 18,964 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 6,250 | 18,750 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.23 per share. | 20 Mar 2025 | 2,197 | 16,767 (0%) | 0% | 41.2 | 90,582 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 36,666 | 36,666 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 27,500 | 27,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 10,000 | 20,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 10,000 | 16,476 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 41.80 per share. | 14 Mar 2025 | 3,762 | 12,714 (0%) | 0% | 41.8 | 157,252 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 18,333 | 18,333 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 36,168 | 36,168 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 25,000 | 25,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 10,000 | 30,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 10,000 | 10,000 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 72.69 per share. | 14 Mar 2024 | 3,524 | 6,476 (0%) | 0% | 72.7 | 256,160 | Common Shares |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Raju Prasad | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 40,000 | 40,000 | - | - | Restricted Stock Units |